Skip to main content

Table 2 Characteristics of the subgroups aged < or ≥ 50 years

From: Analyzing the value of an educational program for psoriasis patients: a prospective controlled pilot study

CategoryNo. (%)p-value
<50a
(n = 28)
≥50a
(n = 25)
Group
 Control n (%)15 (53.6)14 (56)1,00a
 Intervention n (%)13 (46.4)11 (44)
Gender
 Female n (%)6 (21.4)13 (52)0,0254a
 Male n (%)22 (78.6)12 (48)
Age
 Mean (SD)37.71 (9.54)56.36 (4.31)P < 0.0001b
 Median (25%; 75%)39.0 (28.5; 45.75)56.0 (53.0; 58.5)
Self-reported BSA
 Mean (SD)10.75 (20.06)6.10 (14.26)0,21c
 Median (25%; 75%)4.0 (2.0; 9.0)2.0 (0.275; 5.0)
DLQI
 Mean (SD)5.89 (6.01)6.92 (7.94)0,73c
 Median (25%; 75%)4.0 (1.0; 9.0)4.0 (2.0; 9.5)
Disease duration
 Mean (SD)14.63 (9.68)21.92 (14.7)0,0383b
 Median (25%; 75%)14.0 (7.0; 20.0)19.0 (10.5; 34.0)
BMI
 Mean (SD)28.44 (6.34)29.72 (6.26)0,31c
 Median (25%; 75%)26.45 (24.3; 32.7)29.0 (25.25; 32.1)
Comorbidity
 Psoriatic arthritis, n (%)6 (21.4)12 (48)0,0492a
 Depression, n (%)3 (11.1)8 (32)0,09a
 Allergy, n (%)7 (25.9)10 (40)0,38a
 Hypertension, n (%)7 (25.9)12 (48)0,15a
 Cardiovascular diseases, n (%)1 (3.7)2 (8)0,60a
 Hypercholesterolemia, n (%)4 (14.8)7 (28)0,32a
 COPD, asthma, n (%)2 (7.4)7 (28)0,07a
 Hepatitis, cirrhosis of the liver, other liver diseases, n (%)1 (3.7)2 (8)0,60a
 Diabetes mellitus, n (%)2 (7.4)3 (12)0,66a
 Cancer, n (%)01 (4)0,48a
 No comorbidities, n (%)11 (40.7)3 (12)0,0287a
 Current smoker, n (%)9 (32.1)11 (47.8)0,39a
 Ex-smoker, n (%)8 (28.6)8 (34.8)0,76a
 Non-smoker, n (%)11 (39.3)4 (17.4)0,13a
  1. aFisher’s exact test; bunpaired t-test; cMann-Whitney test; a age, BMI Body-Mass-Index, BSA Body Surface Area (range: 0–100), COPD Chronic obstructive pulmonary disease, DLQI Dermatology Life Quality Index, n number, SD standard deviation, 25% 25th percentile, 75% 75th percentile
  2. Significant p values (p<0,05) are written in boldface